NGeneBio Co

NGeneBio Co Short-term Debt

The Short-Term Debt of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 4.60 B KRW. In the previous year, Short-Term Debt was 2.00 B KRW — a change of 130.00% (higher).

Short-term Debt

4.60 BKRW

YoY

130.00%

Last updated:

Short-Term Debt of NGeneBio Co is 2024 4.60 B KRW. Short-Term Debt of NGeneBio Co was 2023 2.00 B KRW. It decreases by 130.00% higher compared to the previous year.

The NGeneBio Co Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
0.00 KRW
Jan 1, 2019
3.40 B KRW
Jan 1, 2020
5.00 B KRW
Jan 1, 2021
6.10 B KRW
Jan 1, 2022
2.50 B KRW
Jan 1, 2023
2.00 B KRW
Jan 1, 2024
4.60 B KRW
The NGeneBio Co Short-term Debt history
YEARShort-term DebtYoY
4.60 BKRW+130.00%
2.00 BKRW-20.00%
2.50 BKRW-59.02%
6.10 BKRW+22.00%
5.00 BKRW+47.06%
3.40 BKRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Short-Term Debt of NGeneBio Co is 4.60 B KRW in 2024.

Short-Term Debt of NGeneBio Co changed from 2.00 B KRW to 4.60 B KRW, representing a 130.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NGeneBio Co

All Key Metrics — NGeneBio Co